Navigation Links
MDS Analytical Technologies' Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker
Date:2/4/2009

SUNNYVALE, CA, Feb. 4 /PRNewswire-FirstCall/ - MDS Analytical Technologies, a leader in innovative solutions for drug discovery and life sciences research, today announced that its Arcturus(R) Laser Capture Microdissection (LCM) instruments were used by researchers at the University of Cincinnati (UC) in their discovery of genetic variations that may prove to be key predictors of risk for colon cancer and indicators of the disease's progression.

Researchers hope that these important findings will provide doctors with much improved diagnostic tools for colon cancer. By identifying people that carry these genetic variations, doctors will be better equipped to determine the course of treatment for patients with the disease. This data may also prove important as doctors advise patients on health and lifestyle choices that may influence one's risk of developing the disease.

"MDS Analytical Technologies is very pleased that its Arcturus line of LCM instruments played such a key role in this important discovery that may move us even closer to preventing more people from developing colon cancer," said Andy Boorn, President of MDS Analytical Technologies. "By maintaining custody of the sample throughout the microdissection process, the Arcturus system removed any guesswork from the experiment, and allowed the researchers at the University of Cincinnati to collect only their desired material for this important study."

As reported in the January 16, 2009 issue of PLoS Genetics, a peer-review, open-access scientific journal published by the U.S. Public Library of Science, scientists at UC used Arcturus(R) LCM systems to investigate the role that the abnormal regulation of a known prostate cancer biomarker - alpha-methylacyl-coenzyme A racemase (AMACR) - plays in colon cancer. AMACR is a protein that breaks down branched-chain fatty acids, which are found in red meats and dairy products, and are suspected to be risk factors for the disease.

"AMACR was recently shown to have abnormal expression patterns in colon cancer, but not much was known about how it's regulated at the gene level," said Shuk-mei Ho, Ph.D., Chair of UC's Department of Environmental Health and senior author of the study. "Uncovering how the gene is abnormally activated in cancer will give us a better understanding of how to treat the disease in the end."

To find answers, scientists at UC, along with researchers at the University of Massachusetts, used Arcturus(R) LCM instruments to enrich a homogenous population of cancer cells from colon carcinoma tissue, so that their data would not be obscured by non-carcinoma material that otherwise would be included in the analysis. Scientists analyzed a series of samples that represented the entire colon cancer progression, comparing the genetic sequences of the laser capture microdissected colon carcinoma cells with sequences from a general population. Comparative sequencing of the two groups of samples revealed the genetic variations that may be the triggers for abnormal protein expression found in colon cancer.

"Only by using LCM were we able to uncover these deletions in the AMACR sequence," Dr. Ho said. "We needed to look at only the cancer cells versus normal cells, and LCM was the only way to achieve this level of sensitivity."

In addition to the novel deletions, the study identified putative transcription factors that, under normal circumstances, may bind to the deleted sequence to regulate gene expression. The study also found a novel genetic variant in AMACR that is present in the general population, and which may influence the course of how colon cancer may progress.

"We need to start paying closer attention to how the environment in which we live and the things we put in our bodies interact with our genetic makeup to influence our cancer risk," Dr. Ho added.

The UC research team expects to expand this research into a multi-center study in the near future. The project is currently funded by the National Institutes of Health and the U.S. Army Prostate Cancer Program.

ArcturusXT(TM) System

MDS Analytical Technologies will present the ArcturusXT(TM) system at the American Academy of Forensic Sciences Annual Meeting 2009, February 18-20 in Denver, CO (MDS Analytical Technologies' booth # 606). The system will also be presented at the American Association for Cancer Research Annual Meeting 2009, April 19-22 in Denver, CO (MDS Analytical Technologies' booth # 546).

About Arcturus(R) LCM Instruments

The Arcturus(R) LCM instruments isolate pure cell populations from heterogeneous populations of cells by employing MDS Analytical Technologies' exclusive infrared (IR) laser-based capture technology, which has been designed to maintain biomolecule integrity within the microdissected samples for use in downstream analyses. Whether researchers are using LCM alone or in combination with the ultraviolet laser cutting option, the gentle non-damaging IR capture technology allows the custody of the microdissected sample to be maintained throughout the process. This gives researchers confidence and assurance that their desired material has been collected. Enrichment of specific populations of cells through this process enables researchers to perform sensitive and specific molecular analyses, otherwise not possible without the use of LCM. Arcturus(R) LCM instruments are for research use only and not intended for clinical or diagnostic purposes.

About MDS Analytical Technologies

MDS Analytical Technologies, a business unit of MDS Inc., is focused on the research, design, manufacture and marketing of state-of-the-art tools for mass-spectrometry, drug discovery and bioresearch. MDS Analytical Technologies' products are designed to help accelerate the complex process of discovering and developing new drug compounds, and are sold to research scientists around the world. The mass-spectrometer product lines are also sold globally through joint ventures with two of the world's leading analytical instrumentation and life sciences companies, Life Technologies Corp. and PerkinElmer, Inc. Find out more at www.mdssciex.com or www.moleculardevices.com.

About MDS Inc.

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.


'/>"/>
SOURCE MDS Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Polymathic Analytical Labs Launches New Website
2. Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC
3. Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
4. Associates of Cape Cod (ACC) and MDS Analytical Technologies Collaborate to Offer a More Robust LAL Endotoxin Assay Platform
5. MDS Analytical Technologies Acquires Blueshift Biotechnologies
6. Pace Analytical Services, Inc., Purchases Laucks Testing Laboratory, Inc.
7. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
8. Dilon Technologies Slant15(TM) and LEHR Collimators Enhance Imaging Capabilities
9. Patient Safety Technologies Closes $2.55 Million Financing
10. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
11. Medusa Medical Technologies Announces Integration of Siren ePCR Suite(TM) with Philips HeartStart MRx Monitor/Defibrillator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology: